Every compound in the longevity pharmacopeia, graded on four-tier evidence and updated within 24 hours of new publications.
| Compound | Mechanism | Evidence | Key outcome | Source | Updated |
|---|---|---|---|---|---|
| Rapamycin sirolimus · RAP-001 | Rapamycin binds to FKBP12 and inhibits mechanistic target of rapamycin complex 1 (mTORC1),… | Moderate | Surrogate endpoints | PEARL 2024 · immune fn | May 2026 |
| Metformin metformin HCl · MET-002 | Metformin activates AMP-activated protein kinase (AMPK), a master metabolic regulator that… | Moderate | HR 0.93 (0.88–0.99) | Campbell 2017 meta · ACM | May 2026 |
| NMN | NMN (nicotinamide mononucleotide) is a direct NAD+ precursor that replenishes intracellula… | Emerging | Surrogate endpoints | Yoshino 2021 · insulin sens | May 2026 |
| NR nicotinamide riboside · NR-004 | Nicotinamide riboside (NR) is a NAD+ precursor that increases intracellular NAD+ availabil… | Emerging | Surrogate endpoints | Martens 2020 · aortic stiff | May 2026 |
| D + Q dasatinib + quercetin · SEN-005 | D + Q (dasatinib + quercetin) functions as a senolytic by selectively inducing apoptosis i… | Emerging | No pooled HR | Kirkland 2023 · Phase II | May 2026 |
| GLP-1 agonists | GLP-1 receptor agonists bind to GLP-1R on pancreatic beta cells and extrapancreatic tissue… | Strong | HR 0.80 (0.72–0.90) | SELECT 2023 · MACE | May 2026 |
| SGLT2 inhibitors empagliflozin / dapagliflozin · SGL-007 | SGLT2 inhibitors block sodium-glucose cotransporter 2 in the proximal renal tubule, reduci… | Strong | HR 0.62 (CV death) | EMPA-REG 2015 | May 2026 |
| Acarbose | Acarbose inhibits α-glucosidase enzymes in the small intestine, slowing glucose absorption… | Moderate | ITP lifespan data | ITP 2014 · mouse only | May 2026 |
| Taurine | Taurine activates AMP-activated protein kinase (AMPK) through increased cellular energy st… | Emerging | — | Evidence under review | Jun 2026 |
| Berberine | Berberine functions as an allosteric activator of AMP-activated protein kinase (AMPK), inc… | Emerging | — | Evidence under review | Jun 2026 |
| 17α-Estradiol | 17α-Estradiol (17αE2) is a non-aromatizable estrogen that activates estrogen receptor-α an… | Emerging | ITP lifespan data | NIA ITP · male mice only | Jun 2026 |
| Spermidine | Spermidine enhances autophagy through inhibition of the acetyltransferase EP300, thereby p… | Emerging | — | Evidence under review | Jun 2026 |
| Urolithin A | Urolithin A is a postbiotic metabolite derived from dietary ellagitannins that activates m… | Emerging | — | Evidence under review | Jun 2026 |
| Fisetin | Fisetin is a flavonoid that selectively induces apoptosis in senescent cells through activ… | Emerging | — | Evidence under review | Jun 2026 |
| Showing 14 tracked interventions · Key outcomes shown where published pooled data exists · Surrogate endpoints noted where no hard outcome HR is available · Full profiles available to subscribers → | |||||
Evidence strength is assigned on a four-tier ladder: Strong (Phase III evidence or multiple concordant RCTs with society endorsement), Moderate (≥ 2 RCTs or one large RCT plus meta-analytic support), Emerging (single RCT or pooled small-trial signal), and Insufficient (pre-clinical or early human signal only).
Every profile is reviewed by the editorial team before publication. Where pooled hazard ratios are shown, the source meta-analysis or trial is cited. All claims link to primary sources in the full subscriber profiles.